BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!

Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what’s driving the FDA’s increased enforcement and why these shutdowns could signal a broader shift in the compounded medication market.Joined by Sabina Hemmi from glpwinner.com, we break down the key differences between 503A and 503B pharmacies, what these changes mean for supply and patient access, and why delays in prescriptions may be on the horizon. We also dive into the growing legal battles between pharma companies and telehealth providers and what that could mean for the future of affordable GLP-1 options.If you’re using or considering compounded GLP-1s, this episode covers what you need to know right now and what could be coming next.